NLRP3 and Parkinson disease: The oral administration of the small molecule NLRP3 inhibitor MCC950 in mice inhibits inflammasome activation and effectively relieves Parkinson’s disease-related motor dysfunction, nigrostriatal dopaminergic degeneration, and α-synuclein aggregates [87].